SPOTLIGHT: Erbitux gets first-line status


The cancer drug Erbitux can be marketed as a first-line treatment for colon cancer, now that the FDA has OK'd a label change. The drug is made and marketed by ImClone Systems and Bristol-Myers Squibb. Release

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.